ANI PHARMACEUTICALS, INC Accumulated Other Comprehensive Income
ANI PHARMACEUTICALS, INC (ANIP) had Accumulated Other Comprehensive Income of -$327.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-07
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$327.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $479.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.03M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $2.81M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$327.00K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $479.00K 10-Q · filed 2026-05-08 |
| 2025-12-31 | $1.03M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $2.81M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $3.31M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $3.61M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $5.34M 10-K · filed 2026-02-27 |
| 2024-09-30 | $5.37M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $8.33M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $9.41M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $8.86M 10-K · filed 2025-02-28 |
| 2023-09-30 | $14.08M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $13.73M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $11.13M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $12.17M 10-K · filed 2024-02-29 |
| 2022-09-30 | $10.04M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $5.43M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $2.71M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$3.06M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$4.24M 10-Q · filed 2021-11-01 |
| 2021-06-30 | -$5.43M 10-Q · filed 2021-08-06 |
| 2021-03-31 | -$5.03M 10-Q · filed 2021-05-07 |
| 2020-12-31 | -$11.44M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$13.11M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$14.05M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$11.69M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$4.87M 10-K · filed 2021-03-11 |
| 2019-09-30 | -$6.04M 10-Q · filed 2019-11-06 |
| 2019-06-30 | -$5.01M 10-Q · filed 2019-08-07 |
| 2019-03-31 | -$2.20M 10-Q · filed 2019-05-09 |
| 2018-12-31 | -$379.00K 10-K · filed 2020-02-27 |
| 2018-09-30 | $533.00K 10-Q · filed 2018-11-06 |
| 2018-06-30 | $216.00K 10-Q · filed 2018-08-07 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |